{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:02:51Z","timestamp":1784530971768,"version":"3.55.0"},"reference-count":43,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Cervical dystonia (CD) is a focal dystonia typically treated with botulinum toxin type A (BoNT-A), but objective biomarkers of disease state and treatment response are limited. In a prospective controlled observational study with within-subject phase comparison, we evaluated clinical, neurophysiological, and biochemical markers at two time points (waning and peak response phases) within the BoNT-A injection interval in 30 CD individuals (with caput, collis and mixed patterns) and 25 healthy controls. We measured clinical status (TWSTRS and VAS pain), neurophysiology (F-wave minimal latency (F-min) and cutaneous silent period (CSP) indices) and plasma biochemical markers (neurofilament light chain (NfL) and zonulin). Compared with controls, CD patients showed lower NfL levels, higher zonulin, shorter CSP end duration and shorter CSP-derived central conduction time (CSP-CCT); nerve conduction velocity and CSP onset were similar. From waning to peak, TWSTRS (all subscales) and VAS improved, zonulin decreased, NfL increased, CSP end duration and CSP-CCT increased, and Fmin slightly prolonged. Changes in CSP measures correlated with pain (VAS and TWSTRS pain), while zonulin changes showed no significant correlations and NfL changes correlated weakly\/negatively with CSP end time. Phase-dependent changes in biochemical and neurophysiological markers were observed alongside clinical measures across the BoNT-A treatment cycle in CD, suggesting potential associations between peripheral biochemical markers, central inhibitory measures, and treatment phase. These findings may warrant further investigation of multimodal biomarker approaches in CD.<\/jats:p>","DOI":"10.3390\/toxins18070314","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:09:09Z","timestamp":1784527749000},"page":"314","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarkers, Neurophysiological and Clinical Correlates Following Botulinum Toxin Treatment in Various Clinical Presentations of Cervical Dystonia: A Controlled Study Across Peak and Waning Response Phases"],"prefix":"10.3390","volume":"18","author":[{"given":"Artur","family":"Dru\u017cd\u017c","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Prince Mieszko I Poznan Medical University of Applied Sciences, 60-320 Pozna\u0144, Poland"},{"name":"Department of Neurology, Municipal Hospital, 61-285 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Dudzic","sequence":"additional","affiliation":[{"name":"Department of Neurology, Municipal Hospital, 61-285 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Poszwa","sequence":"additional","affiliation":[{"name":"Laboratory of Neurobiology, Department of Neurology, Poznan University of Medical Sciences, 60-355 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0109-4331","authenticated-orcid":false,"given":"Igor","family":"Bednarski","sequence":"additional","affiliation":[{"name":"Department of Neurology, Central University Hospital, 92-213 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6166-9424","authenticated-orcid":false,"given":"Katarzyna","family":"Hojan","sequence":"additional","affiliation":[{"name":"Department of Occupational Therapy, Poznan University of Medical Sciences, 60-781 Pozna\u0144, Poland"},{"name":"Department of Rehabilitation, Greater Poland Cancer Centre, 61-866 Pozna\u0144, Poland"},{"name":"Neurorehabilitation Ward, Greater Poland Provincial Hospital, 60-479 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8241-0403","authenticated-orcid":false,"given":"Jolanta","family":"Dorszewska","sequence":"additional","affiliation":[{"name":"Laboratory of Neurobiology, Department of Neurology, Poznan University of Medical Sciences, 60-355 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/mds.29387","article-title":"Isolated Cervical Dystonia: Diagnosis and Classification","volume":"38","author":"Albanese","year":"2023","journal-title":"Mov. Disord."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5603\/PJNNS.a2021.0029","article-title":"Botulinum Neurotoxin in Cervical Dystonia Revisited\u2014Recent Advances and Unanswered Questions","volume":"55","author":"Jost","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1055\/s-0028-1109416","article-title":"The phenomenology of cervical dystonia","volume":"77","author":"Reichel","year":"2009","journal-title":"Fortschr. Neurol. Psychiatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mdc3.12172","article-title":"Selection of Muscles for Botulinum Toxin Injections in Cervical Dystonia","volume":"2","author":"Jost","year":"2015","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_5","first-page":"43","article-title":"Are botulinum toxin type A preparations really the same medication? A comparison of three botulinum toxin A for variations in labelled neurological indications","volume":"44","author":"Car","year":"2010","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"176279","DOI":"10.1016\/j.ejphar.2023.176279","article-title":"Botulinum Toxin Type a Antinociceptive Activity in Trigeminal Regions Involves Central Transcytosis","volume":"963","author":"Matak","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pekny, M., Wilhelmsson, U., Stokowska, A., Tatlisumak, T., Jood, K., and Pekna, M. (2021). Neurofilament Light Chain (NfL) in Blood-A Biomarker Predicting Unfavourable Outcome in the Acute Phase and Improvement in the Late Phase after Stroke. Cells, 10.","DOI":"10.3390\/cells10061537"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100550","DOI":"10.1016\/j.ensci.2025.100550","article-title":"The Role of Neurofilament Light (NfL) and Glial Fibrillary Acidic Protein (GFAP) in MS and AQP4-NMOSD: Advancing Clinical Applications","volume":"38","author":"Samadzadeh","year":"2025","journal-title":"eNeurologicalSci"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e42350","DOI":"10.1016\/j.heliyon.2025.e42350","article-title":"Pioneering pain management with botulinum toxin type A: From anti-inflammation to regenerative therapies","volume":"11","author":"Rahmatipour","year":"2025","journal-title":"Heliyon"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/mdc3.14222","article-title":"Interdisciplinary Consensus in Evaluating the Severity Subscale of the Original and Revised Toronto Western Spasmodic Torticollis Rating Scale Through Video-Based Assessment: An Inter-Rater Reliability Study","volume":"11","author":"Kassaye","year":"2024","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Dru\u017cd\u017c, A., Le\u015bniewska-Furs, E., Dudzic, M., Sowi\u0144ska, A., Jurga, S., and Jost, W.H. (2025). Neurophysiological Assessment of F-Wave, M-Wave, and Cutaneous Silent Period in Patients with Caput-Pattern Cervical Dystonia at Waning and Peak Response Phases of Botulinum Toxin Therapy. Toxins, 18.","DOI":"10.3390\/toxins18010021"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Dru\u017cd\u017c, A., Dudzic, M., Sowi\u0144ska, A., Jurga, S., G\u00f3rna, N., and Ka\u017amierski, R. (2026). Neurophysiological Assessment of F-, M-Waves and Cutaneous Silent Period in Patients with Caput Patterns of Cervical Dystonia in the Waning Phase of Botulinum Toxin Therapy. Neurol. Neurochir. Pol., online ahead of print.","DOI":"10.5603\/pjnns.109338"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e70038","DOI":"10.1111\/bpa.70038","article-title":"Neurofilament Light Chain as a Marker of Peripheral Nerve Damage in Vasculitic Neuropathy? A Cross-Compartmental Correlation Analysis in Patients Undergoing Nerve Biopsy","volume":"36","author":"Streit","year":"2026","journal-title":"Brain Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.parkreldis.2022.04.013","article-title":"Neurofilament Assessment in Patients with Cervical Dystonia","volume":"98","author":"Ferrazzano","year":"2022","journal-title":"Park. Relat. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1111\/ene.15972","article-title":"Blood Neurofilament Light Chain as a Surrogate Marker for Dystonia","volume":"30","author":"Wu","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Quartarone, A., and Ruge, D. (2018). How many types of dystonia? Pathophysiological considerations. Front. Neurol., 9.","DOI":"10.3389\/fneur.2018.00012"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1111\/ejn.14414","article-title":"Maladaptive striatal plasticity and abnormal reward-learning in cervical dystonia","volume":"50","author":"Gilbertson","year":"2019","journal-title":"Eur. J. Neurosci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1515\/cclm-2020-1276","article-title":"Biological variation of serum neurofilament light chain","volume":"60","author":"Hviid","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Delnooz, C.C.S., Pasman, J.W., Beckmann, C.F., and van de Warrenburg, B.P.C. (2013). Task-Free Functional MRI in Cervical Dystonia Reveals Multi-Network Changes That Partially Normalize with Botulinum Toxin. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062877"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neures.2018.07.001","article-title":"Metabolic Aspects of Neuronal Degeneration: From a NAD Point of View","volume":"139","author":"Sasaki","year":"2019","journal-title":"Neurosci. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1251384","DOI":"10.1080\/21688370.2016.1251384","article-title":"Zonulin, a Regulator of Epithelial and Endothelial Barrier Functions, and Its Involvement in Chronic Inflammatory Diseases","volume":"4","author":"Sturgeon","year":"2016","journal-title":"Tissue Barriers"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s40520-023-02463-2","article-title":"Serum Zonulin Levels Are Increased in Alzheimer\u2019s Disease but Not in Vascular Dementia","volume":"35","author":"Boschetti","year":"2023","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e965","DOI":"10.1002\/ctm2.965","article-title":"Zonulin and Blood-Brain Barrier Permeability Are Dissociated in Humans","volume":"12","author":"Stuart","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1749-6632.2012.06538.x","article-title":"Zonulin, Regulation of Tight Junctions, and Autoimmune Diseases","volume":"1258","author":"Fasano","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.apsb.2024.10.004","article-title":"Oxidative Stress and Inflammation in the Pathogenesis of Neurological Disorders: Mechanisms and Implications","volume":"15","author":"Dash","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"28171","DOI":"10.1038\/s41598-024-76697-z","article-title":"Serum Zonulin and Colorectal Cancer Risk","volume":"14","author":"Marino","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s43066-024-00351-6","article-title":"Value of Zonulin as a Diagnostic and Prognostic Marker in Different Degrees of Nonalcoholic Fatty Liver Disease","volume":"14","author":"ElGhandour","year":"2024","journal-title":"Egypt. Liver J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/08039488.2020.1715474","article-title":"Serum Zonulin and Claudin-5 Levels in Children with Obsessive-Compulsive Disorder","volume":"74","author":"Aktepe","year":"2020","journal-title":"Nord. J. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Erkan, G.C., Sumnu, A., Ertugrul, G., Ulfer, G., Cakici, C., Aydin, H.C., and Unal, A. (2023). The Relationship between Zonulin and Metabolic Syndrome in Renal Transplant Patients. Clin. Lab., 69.","DOI":"10.7754\/Clin.Lab.2022.220341"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1177\/1352458519863133","article-title":"Biomarkers of Intestinal Barrier Function in Multiple Sclerosis Are Associated with Disease Activity","volume":"26","author":"Silva","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"\u00dclfer, G., Polat, B., Yabalak, A., and \u00c7ak\u0131c\u0131, \u00c7. (2025). Evaluation of Zonulin Levels in Patients with Migraine. BMC Neurol., 25.","DOI":"10.1186\/s12883-025-04058-y"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e0028321","DOI":"10.1128\/mSphere.00283-21","article-title":"Gut Microbiome and Serum Metabolome Alterations Associated with Isolated Dystonia","volume":"6","author":"Ma","year":"2021","journal-title":"mSphere"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Timmers, E.R., Swarte, J.C., Gacesa, R., Bj\u00f6rk, J.R., Weersma, R.K., Tijssen, M.A.J., de Koning, T.J., Harmsen, H.J.M., and Niezen-Koning, K.E. (2023). Gut Microbiome Composition in Dystonia Patients. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032383"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1007\/s12640-021-00378-2","article-title":"Botulinum Injections for Idiopathic Cervical Dystonia: A Longitudinal Study","volume":"39","author":"Yahalom","year":"2021","journal-title":"Neurotox. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/jnnp-2012-303608","article-title":"Long-Term Efficacy and Safety of incobotulinumtoxinA Injections in Patients with Cervical Dystonia","volume":"84","author":"Dressler","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00415-014-7343-6","article-title":"Cervical Dystonia and Pain: Characteristics and Treatment Patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy)","volume":"261","author":"Charles","year":"2014","journal-title":"J. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Park, J., and Chung, M.E. (2018). Botulinum Toxin for Central Neuropathic Pain. Toxins, 10.","DOI":"10.3390\/toxins10060224"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/14737175.2021.1984230","article-title":"Pain in Cervical Dystonia: Mechanisms, Assessment and Treatment","volume":"21","author":"Rosales","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/mus.880171009","article-title":"Normative F Wave Values and the Number of Recorded F Waves","volume":"17","author":"Fisher","year":"1994","journal-title":"Muscle Nerve"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1388-2457(03)00028-2","article-title":"Reference Values of F Wave Parameters in Healthy Subjects","volume":"114","author":"Puksa","year":"2003","journal-title":"Clin. Neurophysiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.clinph.2019.01.002","article-title":"Cutaneous Silent Periods\u2014Part 1: Update on Physiological Mechanisms","volume":"130","author":"Kofler","year":"2019","journal-title":"Clin. Neurophysiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5455\/medarh.2014.68.98-101","article-title":"Cutaneous Silent Period in the Evaluation of Small Nerve Fibres","volume":"68","author":"Denislic","year":"2014","journal-title":"Med. Arch."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1055\/s-0042-1755229","article-title":"Recording Cutaneous Silent Period Parameters in Hereditary and Acquired Neuropathies","volume":"80","author":"Neves","year":"2022","journal-title":"Arq. Neuropsiquiatr."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/7\/314\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:19:29Z","timestamp":1784528369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/7\/314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,19]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["toxins18070314"],"URL":"https:\/\/doi.org\/10.3390\/toxins18070314","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,19]]}}}